The HIP trial is a large pragmatic, multinational, randomised trial of two different
strategies for the management of hypotension in extremely low gestational age newborns
(Standard with dopamine versus a restricted with placebo approach).
HYPOTHESIS: A restricted approach to the management of hypotension in extremely low
gestational age newborns will result in improved neonatal and long-term developmental
outcomes.
PRIMARY OBJECTIVE: To determine whether a restricted approach to the management of
hypotension compared to using dopamine as first line pressor agent in infants born less than
28 weeks of gestation within the first 72 hrs after birth (transitional period), improves
survival without significant brain injury at 36 weeks postmenstrual age (PMA) and improves
survival without moderate or severe neurodevelopmental disability at 2 years corrected age.